The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.

Company Guidance

In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.

Significant Reduction in R&D Expenses

Research and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.

Net Loss Reduction

The company reported a net loss of EUR 5.5 million for the first half of 2025, compared to EUR 13.6 million for the first half of 2024, indicating improved financial management.

Strong Clinical Data for Varoglutamstat

Varoglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney functions in Phase II studies, with notable benefits in diabetic kidney disease patients.

New U.S. Patent for Varoglutamstat

Vivoryon secured a new U.S. composition of matter patent for varoglutamstat, supporting market exclusivity through 2044 with potential for extension.

Preclinical Success in Diabetic Kidney Disease Model

Varoglutamstat showed impressive reductions in inflammation and fibrosis in a diabetic kidney disease mouse model.

Positive Feedback from Scientific Community

The data presented at the European Renal Association Annual Congress and ASN Kidney Week were well received by the nephrology community, increasing interest in varoglutamstat.

Vivoryon Therapeutics AG (GB:0R3M) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0R3M Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	- / -	-0.52	―	―	―
Sep 04, 2025	2025 (Q2)	- / -0.21	-0.63	66.67% (+0.42)	―	―
Jun 17, 2025	2025 (Q1)	- / -	-0.676	―	―	―
Apr 29, 2025	2024 (Q4)	- / -0.27	-0.676	60.21% (+0.41)	―	―
Dec 10, 2024	2024 (Q3)	- / -	-0.413	―	―	―
Sep 12, 2024	2024 (Q2)	-0.63 / -0.63	-0.413	-52.54% (-0.22)	―	―
May 23, 2024	2024 (Q1)	- / -	-0.681	―	―	―
Apr 24, 2024	2023 (Q4)	- / -0.68	-0.681	0.73% (<+0.01)	―	―
Dec 06, 2023	2023 (Q3)	- / -	-0.598	―	―	―
Sep 07, 2023	2023 (Q2)	- / -0.41	-0.598	30.94% (+0.18)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0R3M Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 04, 2025	€1.70	€1.59	-6.47%
Jun 17, 2025	€1.63	€1.60	-1.84%
Apr 29, 2025	€1.80	€1.77	-1.67%
Dec 10, 2024	€2.56	€1.98	-22.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vivoryon Therapeutics AG (GB:0R3M) report earnings?

Vivoryon Therapeutics AG (GB:0R3M) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Vivoryon Therapeutics AG (GB:0R3M) earnings time?

Vivoryon Therapeutics AG (GB:0R3M) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Vivoryon Therapeutics AG stock?

The P/E ratio of Vivoryon Therapeutics AG is N/A.

What is GB:0R3M EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing